Form 4: Pliant Therapeutics Executive Lily Cheung Reports Stock and Option Grants
SEC Form 4 Filing
Pliant Therapeutics' Chief Human Resource Officer, Lily Cheung, received stock and option grants as part of her compensation package.
Summary
- Lily Cheung, Chief Human Resource Officer at Pliant Therapeutics, reported a transaction on January 23, 2025.
- She acquired 25,875 shares of common stock as restricted stock units, which vest in three equal annual installments starting January 16, 2025.
- She also acquired options to purchase 51,750 shares of common stock at an exercise price of $11.14.
- These options vest monthly over four years starting January 1, 2025.
- Following these transactions, Ms. Cheung beneficially owns 50,425 shares of common stock and options for 51,750 shares.
Sentiment
Score: 7
Explanation: The document reflects standard executive compensation practices, which is generally viewed neutrally to slightly positive. The grants are a positive for the executive but not a major market moving event.
Positives
- The stock and option grants align Ms. Cheung's interests with the company's long-term success.
- The vesting schedule encourages continued service to the company.
Industry Context
This is a standard practice for publicly traded companies to grant stock and options to executives as part of their compensation packages.
Comparison to Industry Standards
- Stock option and restricted stock unit grants are common compensation practices for executives in the biotechnology industry.
- Vesting schedules are typically used to incentivize long-term commitment from employees.
- The specific terms of the grants, such as the vesting period and exercise price, are generally aligned with industry norms for companies of similar size and stage.
Stakeholder Impact
- The stock and option grants may have a minor dilutive effect on existing shareholders.
- The grants incentivize the executive to work towards the company's success, which is beneficial for all stakeholders.
Key Dates
| Date | Description |
|---|---|
| 01/23/2025 | Date of the reported stock and option transactions. |
| 01/16/2025 | Start date for vesting of restricted stock units. |
| 01/01/2025 | Start date for vesting of stock options. |
| 01/27/2025 | Date of signature of the Form 4 filing. |
Keywords
stock options, restricted stock units, insider trading, executive compensation, Form 4, Pliant Therapeutics, PLRX, equity grants
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.